Kai-Yuan Tzen has received an MD degree from Taipei Medical College (1968–1975) and an MS degree from The Johns Hopkins Medical Institutions (1977–1979). He served as a Director at the Department of Nuclear Medicine, Chang-Gung Memorial Hospital (1982–2002), and he has been working as a Director at the Department of Nuclear Medicine, NTU Hospital, since 2003. He also has been serving as a Clinical Associate Professor at the Department of Radiology, College of Medicine, NTU, since 2003. He was honored in 2006 the Hsin-Lin Medical Award (Taipei Medical Association); First Place and Second Place Poster Awards: General Practical Specialties Track; Society of Nuclear Medicine 57th SNM Annual Meeting. Salt Lake City, USA (June 5–9, 2010); Best Abstract and Presentation in the Clinical Category Award: Advances in Neuroblastoma Research 2010 meeting, Stockholm, Sweden (June 21–24, 2010). His research interests are among multiple nuclear probe molecular imaging study in neuroblastoma. He has more than 3 years of experience using two PET probes (18FDG and 18FDOPA) and one SPECT probe (123MIBG) to characterize neuroblastoma in children. In 2010, he, among his group, received two awards from the Society of Nuclear Medicine (USA) and one award from the International Conference of Advances in Neuroblstoma Research held in Stockholm, Sweden. In 2011, their fellow researcher received the Young Investigator Award in the USA SNM meeting from June 4–8 in San Antonio, Texas. His research also includes multiple nuclear probe molecular imaging study in AADC deficiency. He, among his colleagues, has experience in using two PET probes (18FDOPA and 18F-fallypride) and one SPECT probe (99mTc-TRODAT-1) to characterize children with congenital AADC deficiency preparing for gene therapy. They tried to define the effect of gene therapy using multiple nuclear probes. They are now starting a multicenter clinical trial on hepatocellular carcinoma detection by 18F-fluorocholine. He also deals with Alzheimer’s disease detection by 11C-PiB (Pittsburgh compound B), an amyloid imaging PET agent.
Biography Updated on 20 March 2012